Clinical Study to Compare the Efficacy of Erbium-Yag Laser or CO2RE Intimate Laser With Sham (COER)

NCT ID: NCT04039555

Last Updated: 2021-02-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-24

Study Completion Date

2020-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial compares the efficacy of two different laser treatments for vaginal atrophy symptoms between them and with sham treatment. Patients will be randomized to one of the two lasers or sham treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients over 45 years of age with one or more AVV symptoms who wish to participate in the study will be included, 2 laser sessions spaced one of another 4-6 weeks, and final tracking visit 4-6 weeks of the last laser session.

Each patient shall be randomly assigned an arm of tto, with laser CO2, or laser Erbium, or sham group

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers
It is a single blind study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Arm - CO2 intimate

Patients will receive 2 sessions of CO2 laser treatment, spaced 4 to 6 weeks apart

Group Type ACTIVE_COMPARATOR

CO2 intimate

Intervention Type DEVICE

Two sessions with CO2 intimate laser for vaginal symptoms treatment

Active Arm - Erbium-yag

Patients will receive 2 sessions of Erbium-Yag laser treatment, spaced 4 to 6 weeks apart

Group Type ACTIVE_COMPARATOR

Erbium-yag

Intervention Type DEVICE

Two sessions with Erbium-yag laser for vaginal symptoms treatment

Sham Arm

Patients will receive 2 sessions of Erbium-Yag laser or CO2 laser treatment with non-therapeutic energy, spaced between 4 and 6 weeks apart

Group Type SHAM_COMPARATOR

CO2 intimate or Erbium-yag

Intervention Type DEVICE

Two sessions of one of the two lasers with no therapeuthical energy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CO2 intimate

Two sessions with CO2 intimate laser for vaginal symptoms treatment

Intervention Type DEVICE

Erbium-yag

Two sessions with Erbium-yag laser for vaginal symptoms treatment

Intervention Type DEVICE

CO2 intimate or Erbium-yag

Two sessions of one of the two lasers with no therapeuthical energy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women older than 45 years with at least one year of amenorrhea and at least one symptom of vulvovaginal atrophy of moderate and / or severe intensity.

Exclusion Criteria

* Hormone treatment in the last three months for vulvovaginal atrophy
* Treatment with vaginal moisturizers in the last week for vulvovaginal atrophy
* Laser treatment in the last 12 months.
* Acute and recurrent infections of the urinary tract in the last 3 months.
* Acute genital infections
* Vaginal prolapse
* Alterations in the area to be treated, such as lacerations, abrasions or ulcers (time of resolution at medical discretion)
* Chronic decompensated noncommunicable diseases
* Women who are pregnant or have given birth in the last 3 months
Minimum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto Palacios

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto Palacios

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COER

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ENT FiberLase CO2 Study
NCT01276418 COMPLETED NA